[1]李峻,顾春林.益气健脾中药并热灌注化疗联合TACE治疗胃癌肝转移的临床应用价值[J].西部中医药,2022,35(02):115-118.[doi:10.12174/j.issn.2096-9600.2022.02.29]
 LI Jun,GU Chunlin.Clinical Value of Qi-benefiting Spleen-invigorating Herbs Combined with Hyperthermic Perfusion Chemotherapy and TACE in the Treatment of Liver Metastasis of Gastric Cancer[J].Western Journal of Traditional Chinese Medicine,2022,35(02):115-118.[doi:10.12174/j.issn.2096-9600.2022.02.29]
点击复制

益气健脾中药并热灌注化疗联合TACE治疗胃癌肝转移的临床应用价值
分享到:

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
35
期数:
2022年02期
页码:
115-118
栏目:
特色医疗
出版日期:
2022-02-15

文章信息/Info

Title:
Clinical Value of Qi-benefiting Spleen-invigorating Herbs Combined with Hyperthermic Perfusion Chemotherapy and TACE in the Treatment of Liver Metastasis of Gastric Cancer
作者:
李峻 顾春林
南京中医药大学附属江苏省中医院,江苏 南京 210026
Author(s):
LI Jun GU Chunlin
Jiangsu Province Hospital of TCM, Nanjing 210026, China
关键词:
胃癌益气健脾热灌注化疗肝动脉插管化疗栓塞
Keywords:
gastric cancer-benefiting spleen-invigoratinghyperthermic perfusion chemotherapyTACE
分类号:
R735
DOI:
10.12174/j.issn.2096-9600.2022.02.29
文献标志码:
B
摘要:
目的分析益气健脾中药并热灌注化疗联合肝动脉插管化疗栓塞(transcatheter arterial chemoembolization,TACE)治疗胃癌肝转移的临床应用价值。 方法选择胃癌肝转移患者72例,随机分为观察组和对照组,各组36例。对照组采用常规TACE疗法,观察组采用益气健脾中药并热灌注化疗联合TACE治疗,比较两组临床总有效率,肿瘤细胞因子[缺氧诱导因子2α(hypoxia inducible factor-2α,HIF-2α)、可溶性白细胞介素2受体(soluble interleukin-2 receptor,sIL-2R)、血管内皮生长因子(vascular endothelial growth factor,VEGF)]、免疫功能指标[CD3+、CD4+/CD8+]水平及不良反应发生情况。 结果观察组总有效率[55.56%(20/36)]明显高于对照组[27.78%(10/36)](P<0.05)。治疗后,两组HIF-2α、sIL-2R及VEGF水平均降低,且观察组治疗后HIF-2α、sIL-2R及VEGF水平与治疗前及对照组治疗后比较,差异有统计学意义(P<0.05)。两组治疗后CD3+、CD4+/CD8+水平上升,观察组治疗后CD3+、CD4+/CD8+水平与治疗前及对照组治疗后比较,差异有统计学意义(P<0.05)。观察组不良反应发生率[27.78%(10/36)]明显低于对照组[52.78%(19/36)](P<0.05)。 结论益气健脾中药并热灌注化疗联合TACE治疗胃癌肝转移可以降低患者肿瘤细胞因子水平,提高相应免疫功能水平,降低不良反应发生率,提高临床治疗有效率。
Abstract:
ObjectiveTo analyze clinical value of Qi-benefiting spleen-invigorating herbs, hyperthermic perfusion chemotherapy and TACE in the treatment of liver metastasis of gastric cancer. MethodsAll 72 patients were chosen, randomized into the observation group and the control group, 36 cases in each group.the control group adopted conventional TACE therapy, and the observation group used Qi-benefiting spleen-invigorating herbs, hyperthermic perfusion chemotherapy and TACE, to compare total effective rates, tumor cytokines (HIF-2α and sIL-2R), VEGF, immune function indexes (CD3+, CD4+/CD8+) and adverse reaction in both groups. ResultsTotal effective rate of the observation group was [55.56%(20/36)], obviously higher than [27.78%(10/36)] of the control group (P<0.05). After the treatment, the levels of HIF-2α, sIL-2R and VEGF lowered in the two groups, and the difference had statistical meaning in the levels of HIF-2α, sIL-2R and VEGF when the observation group after treating was compared with before treating, and the control group after treating (P<0.05). The levels of immune function indexes CD3+, CD4+/CD8+ increased in two groups after treating, when the levels of CD3+, CD4+/CD8+ of the observation group after treating were compared with before treating and the control group after treating, the difference had statistical meaning (P<0.05). The incidence of adverse reaction of the observation group was [27.78% (10/36)], notably lower than [52.78%(19/36)] of the control group (P<0.05). ConclusionQi-benefiting spleen-invigorating herbs, hyperthermic perfusion chemotherapy and TACE could lower tumor cytokines, raise the levels of immune function, reduce the incidence of adverse reaction and lift clinical therapeutic effective rate in the treatment of liver metastasis of gastric cancer.

相似文献/References:

[1]熊墨年,唐晓玲,余炅,等.益气清毒法联合化疗治疗中晚期胃癌的临床观察[J].西部中医药,2011,24(11):35.
[2]张小仙,倪角角,陈辉.舒适护理在晚期胃癌患者中的应用[J].西部中医药,2012,25(12):105.
 ZHANG Xiao-xian,NI Jiao-jiao,CHEN Hui.Application of Comfort Care to the Patients with Gastric Cancer at Advanced Stage[J].Western Journal of Traditional Chinese Medicine,2012,25(02):105.
[3]柳树英,王煜.王自立名老中医从“脾色环唇”论治疾病经验拾萃[J].西部中医药,2013,26(04):42.
 LIU Shuying,WANG Yu.Essence of Famous Veteran TCM Doctor WANG Zili's Experience on Treatment for Diseases with "Spleen Color around the Lip"[J].Western Journal of Traditional Chinese Medicine,2013,26(02):42.
[4]王宏伟,程小丽,许雅清,等.苦马豆素对胃癌细胞中pten和survivin mRNA表达的影响[J].西部中医药,2015,28(12):25.
[5]胡玥,刘沈林.刘沈林教授“胃肾同治”理论探讨及其在胃癌中的应用[J].西部中医药,2015,28(10):72.
[6]朱剑梅,李世军.莲芪胶囊配合化疗治疗胃癌的临床研究[J].西部中医药,2015,28(12):91.
[7]李雅娟.围手术期护理对胃癌根除术患者护理质量的影响[J].西部中医药,2012,25(12):113.
 LI Ya-juan.Influence of Perioperative Care on Nursing Quality of Patients Undergoing Radical Resection of Gastric Cancer[J].Western Journal of Traditional Chinese Medicine,2012,25(02):113.
[8]刘河,刘超,杨世勇.胃癌中医证型与病灶组织中MMP-9、TIMP-2和HER-2表达的相关性分析[J].西部中医药,2017,30(02):134.
 LIU He,LIU Chao,YANG Shiyong.Correlation Analysis btween TCM Syndrome of Gastric Cancer and the Expression of MMP-9, TIMP-2 and HER-2 in Focus Tissue[J].Western Journal of Traditional Chinese Medicine,2017,30(02):134.
[9]王志新,邹玺,胡守友.中药抗胃癌的现代药理机制[J].西部中医药,2016,29(04):137.
 WANG Zhixin,ZOU Xi,HU Shouyou.Modern Pharmacological Mechanism of Herbs Fighting against Gastric Cancer[J].Western Journal of Traditional Chinese Medicine,2016,29(02):137.
[10]李淑玲,刘凯△.李应东教授从脾气虚论治高脂血症[J].西部中医药,2017,30(03):53.
 LI Shuling,LIU Kai.Professor LI Yingdong′s Treatment for Hyperlipidemia from Spleen-Qi Deficiency[J].Western Journal of Traditional Chinese Medicine,2017,30(02):53.

备注/Memo

备注/Memo:
李峻(1980—),男,硕士学位,主治医师。研究方向:胃肠疾病的中医药诊治。2017年度南京市医学科技发展项目(ZKX1701)。
更新日期/Last Update: 2022-06-22